April 7, 2026
“Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide. The stock plummeted on Monday, hitting its lowest level since June 2021. The Danish drugmaker is also navigating… Continue Reading…

Recent Comments